May. 26, 2016
Currently, Chinese companies wishing to commercialize pharmaceuticals need to manufacture them themselves. In a bid to encourage drug-innovation and reduce costs associated with in-house manufacturing - China's State Council has announced a detailed pilot plan for the "Marketing Authorization Holder System". The plan, first to be implemented in 10 provinces in China, allows domestic drug R&D institutions and individuals to apply for and hold drug product licenses without having to become drug manufacturers themselves.